Readystate Asset Management LP Sells 26,114 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Readystate Asset Management LP trimmed its holdings in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 60.5% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 17,040 shares of the company's stock after selling 26,114 shares during the quarter. Readystate Asset Management LP's holdings in iTeos Therapeutics were worth $102,000 as of its most recent filing with the SEC.

A number of other large investors have also bought and sold shares of ITOS. BVF Inc. IL bought a new stake in iTeos Therapeutics during the 4th quarter worth approximately $17,856,000. JPMorgan Chase & Co. increased its stake in iTeos Therapeutics by 342.7% during the 4th quarter. JPMorgan Chase & Co. now owns 2,068,796 shares of the company's stock worth $15,888,000 after purchasing an additional 1,601,477 shares in the last quarter. Boxer Capital Management LLC bought a new position in shares of iTeos Therapeutics during the 4th quarter worth approximately $7,272,000. Jacobs Levy Equity Management Inc. grew its stake in shares of iTeos Therapeutics by 347.9% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 922,134 shares of the company's stock worth $7,082,000 after acquiring an additional 716,271 shares in the last quarter. Finally, Millennium Management LLC grew its stake in shares of iTeos Therapeutics by 1,008.8% during the 4th quarter. Millennium Management LLC now owns 411,072 shares of the company's stock worth $3,157,000 after acquiring an additional 373,999 shares in the last quarter. 97.16% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on ITOS shares. Raymond James Financial set a $12.00 price target on shares of iTeos Therapeutics in a research note on Wednesday, May 14th. Leerink Partners reaffirmed a "market perform" rating and set a $9.00 price target (down from $47.00) on shares of iTeos Therapeutics in a research note on Wednesday, May 14th. Leerink Partnrs cut shares of iTeos Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, May 14th. HC Wainwright cut shares of iTeos Therapeutics from a "buy" rating to a "neutral" rating in a research note on Wednesday, May 14th. Finally, Piper Sandler cut shares of iTeos Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Monday, July 21st. Six equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $15.64.

Insider Activity

In other news, CEO Michel Detheux sold 43,883 shares of the business's stock in a transaction dated Tuesday, June 10th. The shares were sold at an average price of $10.02, for a total value of $439,707.66. Following the completion of the sale, the chief executive officer owned 153,903 shares of the company's stock, valued at approximately $1,542,108.06. The trade was a 22.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Bioventures 2018 L.P. Mpm sold 630,191 shares of the business's stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $8.06, for a total transaction of $5,079,339.46. Following the completion of the sale, the insider directly owned 2,108,594 shares of the company's stock, valued at approximately $16,995,267.64. The trade was a 23.01% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,939,307 shares of company stock valued at $16,202,116. 12.50% of the stock is owned by company insiders.

iTeos Therapeutics Stock Down 0.1%

Shares of NASDAQ:ITOS traded down $0.02 during midday trading on Monday, hitting $10.16. The stock had a trading volume of 157,159 shares, compared to its average volume of 922,559. iTeos Therapeutics, Inc. has a 12 month low of $4.80 and a 12 month high of $18.13. The business's 50-day simple moving average is $9.88 and its 200-day simple moving average is $8.00. The company has a market cap of $388.63 million, a P/E ratio of -3.34 and a beta of 1.49.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last released its quarterly earnings data on Monday, April 28th. The company reported ($0.80) EPS for the quarter, topping analysts' consensus estimates of ($0.94) by $0.14. As a group, equities analysts predict that iTeos Therapeutics, Inc. will post -3.49 earnings per share for the current year.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.